Citations

Institution: Mayo Clinic Clear

Showing 10 of 108094 citations.

Regional Nerve Blocks for Primary Total Knee Arthroplasty in Chronic Opioid Patients
Ledford, Cameron K. , Giusti, Nick , Ubl, Daniel S. , Kapple, Mason R., Clendenen, Steven R. , Giusti, Nicolas E , Wilke, Benjamin K. , Ledford, Cameron K

The Journal of Knee Surgery | July 30, 2025 | Volume: 39 | Issue: 01 | Pages: 057-062

10.1055/a-2672-2907 | PMID 40738134 Get It

Abstract Postoperative pain control after total knee arthroplasty (TKA) remains challenging, particularly in patients utilizing chronic opioids preoperatively. Our study aimed to evaluate the effect of regional nerve blockade on perioperative pain control outcomes after TKA in patients using or not using chronic preoperative opioids. A retrospective review of our institutional database identified 434 chronic opioid patients defined as documented ongoing use greater than 3 months prior to contemporary TKA. Patients were 1:1 matched to nonopioid users based upon age, sex, body mass index, and regional block type (single-shot adductor canal block [ACB, 29%], 3-day ACB catheter [31%], or no block [41%]). All patients underwent primary TKA using periarticular injections and contemporary multimodal pain management. Immediate and 90-day postoperative outcomes, including Knee Osteoarthritis Outcome Score, Junior (KOOS, Jr), were compared via univariate analysis among the matched cohort and regional block type among chronic opioid patients. Chronic opioid patients demonstrated higher inpatient opioid use than controls (90 vs. 65 oral morphine equivalents [OMEs], respectively, p < 0.01), but no significant differences existed in length of stay (LOS), discharge pain scores, 90-day readmission or KOOS, Jr (all p ≥ 0.05). When comparing chronic opioid patients according to block type, those receiving no block had the highest LOS (1.6 days, p < 0.01), discharge pain score (5.0, p < 0.01), and inpatient opioid use (80 OMEs, p < 0.01) compared with either ACB. The subgroup receiving an ACB catheter demonstrated a significantly higher 90-day readmission rate (9%, p < 0.05). Patients utilizing chronic opioids preoperatively require more opioids in the immediate postoperative period after TKA compared with nonopioid users despite contemporary modalities. Nonetheless, the use of any type of ACB provides improved pain control in these patients.
Topical hemostatic agents in endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review
Gralnek, Ian M. , Alkandari, Asma , Alali, Ali , Haidry, Rehan , Papaefthymiou, Apostolis , Radaelli, Franco , Subramaniam, Sharmila , Fuccio, Lorenzo , Bhandari, Pradeep , Alali, Ali , Papaefthymiou, Apostolis , Radaelli, Franco , Subramaniam, Sharmila , Fuccio, Lorenzo

Endoscopy | July 30, 2025 | Volume: 57 | Issue: 10 | Pages: 1150-1173

10.1055/a-2646-7556 | PMID 40738122 Get It

Abstract Gastrointestinal (GI) endoscopy has evolved from a diagnostic tool into a therapeutic modality, leading to a higher incidence of bleeding complications during and after procedures. To address this issue, various hemostatic agents have been developed, including injectable, mechanical, thermal, and topical products. Topical hemostatic agents, available in powder or gel forms, can be used as standalone treatments or as adjuncts to traditional hemostatic therapies to control or prevent bleeding. This Technical and Technology Review examines the commercially available topical hemostatic agents used in endoscopy, specifically Purastat, TC-325 Hemospray, EndoClot PHS, Nexpowder, Ankaferd Blood Stopper, and CG GEL. A systematic literature review was conducted up to January 2025, focusing on randomized controlled trials (RCTs), meta-analyses, and observational studies. Each product was assessed for its composition, mechanism of action, regulatory status, mode of use, efficacy, safety, and financial considerations. Purastat showed 94% efficacy in acute GI bleeding, reducing delayed bleeding to 4.3% in endoscopic submucosal dissection (ESD) and endoscopic mucosal resection cases, with significantly lower thermal device usage. TC-325 Hemospray achieved 85%–98.5% primary hemostasis in upper and lower GI bleeding, with pooled hemostasis rates of 93.1% and rebleeding rates of 8.9%. It was also effective in malignancy-related bleeding, with hemostasis success up to 100%. EndoClot PHS demonstrated 76%–100% hemostasis efficacy, comparable with TC-325, with rebleeding rates of 24%–25%. It showed prophylactic potential post-ESD, with rebleeding rates of 7.3%–9.1%. Nexpowder achieved 94% hemostasis in refractory upper GI bleeds and reduced rebleeding in lower GI bleeds to 5.5% at 28 days. Ankaferd Blood Stopper demonstrated 73%–100% hemostasis across various GI bleeding sources, including peptic ulcers and malignancies, though further data on rebleeding are needed. Topical hemostatic agents offer effective options for managing GI bleeding. Products like Purastat, TC-325 Hemospray, EndoClot PHS, Nexpowder, Ankaferd Blood Stopper, and CG GEL have shown promising results in achieving hemostasis; however, further RCTs and cost-effectiveness analyses are needed to better establish their roles in endoscopic practice.
Ischemia-Reperfusion Injury in a Composite Tissue Microsurgical Model
Sarcon, Aida K. , Wan, Rou , Reisdorf, Ramona L., Jacobs, J. Howard, Selim, Omar , Boynton, Felicia D. Duke , Gingery, Anne , Zhao, Chunfeng , Moran, Steven L. , Gingery, Anne , Jacobs, Julia F., Behfar, Atta

Plastic & Reconstructive Surgery | July 30, 2025 | Volume: 157 | Issue: 2 | Pages: 218e-230e

10.1097/prs.0000000000012343 | PMID 40737620 Get It

Background: The authors present a novel microsurgical model to investigate ischemia-reperfusion (I/R) injury in composite tissue (muscle/skin) using a musculocutaneous flap. I/R was induced in a rodent biceps femoris musculocutaneous flap through collateral ligation and arteriovenous clamping. The authors hypothesized that I/R flaps would show greater tissue damage compared with sham. Methods: Male rats were randomized into I/R ( n = 10) and sham ( n = 9) groups. The I/R group underwent flap elevation, collateral ligation, 3 hours of arteriovenous clamping, followed by reperfusion. The sham group had flap elevation only. Perfusion was monitored using laser-speckle imaging, and flap discoloration was assessed with blinded skin ischemia necrosis scores. Serum and the composite tissue (skin/muscle) were analyzed for injury on postoperative days (PODs) 1 or 3. Results: Clamping reduced perfusion ( P = 0.00), whereas unclamping increased perfusion ( P <0.00). Over time, flaps exposed to I/R were more ischemic (estimate, 0.39; P = 0.02). At POD1, the injury group had higher serum creatine kinase ( P = 0.04) and potassium ( P = 0.00) than the sham group. The injury group had more muscle apoptosis (34.7% versus 5.2%; P = 0.03), myonecrosis (30.3% versus 14.1%; P = 0.04), and inflammation (13.7% versus 4.9%; P = 0.02) than the sham group; myonecrosis and inflammation persisted into POD3. Skin apoptosis and inflammation were similar. Conclusions: This model reliably reproduces I/R injury with a 3-hour ischemic period followed by early reperfusion. Animals subjected to the authors’ technique showed greater tissue damage than the sham group, with muscle being more vulnerable than skin. Serum showed peak muscle injury at 24 hours, and histologic analysis showed myonecrosis and inflammation through 72 hours. This suggests that less than 24 hours’ reperfusion (eg, critical window) may serve as the optimal time for possible intervention. Clinical Relevance Statement: I/R injury is a complex phenomenon affecting vascular composite tissues. The mitochondrial superoxide dismutase may be more specific for I/R injury. There may be a critical window within which to mitigate injury (<24 hours after reperfusion). The authors’ model helps investigate muscle/skin I/R injury.
Bridging the Gap: The Role of Doctoral Capstone Students in Knowledge Translation & Promoting Evidence-Based Practice in Physical Rehabilitation
Taylor, Christopher , Taylor, Christopher

The American Journal of Occupational Therapy | July 30, 2025 | Volume: 79 | Issue: Supplement_2 | Pages: 7911500338p1-7911500338p1

10.5014/ajot.2025.79s2-po327 Get It

Abstract Date Presented 04/03/2025 The goal of this study is to identify current successes, limiting barriers, and overarching trends in knowledge translation, specifically as they relate to OT doctoral capstone students. Primary Author and Speaker: Christopher Taylor
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Rangarajan, Hemalatha G. , Satwani, Prakash , Chen, Min , Wudhikarn, Kitsada , Marks, David I. , Kelly, Matthew S. , Farhadfar, Nosha , Prestidge, Tim , Hossain, Nasheed , Liu, Hongtao , Hashmi, Shahrukh K. , Modi, Dipenkumar , Winestone, Lena E. , Boghdadly, Zeinab El , Chemaly, Roy F. , Dandoy, Christopher E. , Hill, Joshua A. , Huppler, Anna R. , Riches, Marcie , Herr, Megan M. , Martens, Michael J , Kelkar, Amar H , Ringden, Olov , Friend, Brian D , Kelly, Matthew S , Prestidge, Tim , Hossain, Nasheed M , Liu, Hongtao , Hashmi, Shahrukh K , Modi, Dipenkumar , Winestone, Lena E , Murthy, Hemant S , Perales, Miguel-Angel , Chemaly, Roy F , Dandoy, Christopher E , Hill, Joshua A , Huppler, Anna R , Auletta, Jeffery J , Martens, Michael J. , John, Samuel, Fabrizio, Vanessa A , Hsieh, Emily M. , Doherty, Erin , Ringdén, Olle , Murthy, Hemant S. , Perales, Miguel‐Angel , Auletta, Jeffery J.

Blood Advances | July 30, 2025 | Volume: 9 | Issue: 21 | Pages: 5489-5500

10.1182/bloodadvances.2025016149 | PMID 40737539 Get It

Abstract Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL). We report infectious complications for 100 days (D100) following tisa-cel therapy in 471 pediatric and young adults (median age 13.8 years) with R/R B-ALL reported from September 2017 to June 2022. By D100, 137 (29%) patients had an infectious event, with an infection density of 0.542 per 100 person-days at risk. D100 cumulative incidences of bacterial, viral, and fungal infections were 14.1%, 11.6%, and 1.3%, corresponding to infection density scores of 0.296, 0.213, and 0.033 per 100 person-days at risk, respectively. In a multivariable analysis, receipt of ≥3 lines of therapy before tisa-cel (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.13-3.08; P = .015), any-grade cytokine release syndrome (HR, 1.78; 95% CI, 1.17-2.71; P = .007), and lack of neutrophil recovery (HR, 2.63; 95% CI, 1.47-4.69; P = .001) were associated with an increased risk for any infection. Similar associations were observed for bacterial infections, with the addition of younger age as an adverse risk (&lt;6 vs 6-15 years; HR, 2.38; 95% CI, 1.23-4.61; P = .01). Risk factors for viral infections included increasing age (1-year increase; HR, 1.05; 95% CI, 1.01-1.09; P = .016), prior history of any infection (HR, 2.76, 95% CI, 1.40-5.46; P = .004), and prior hematopoietic cell transplant (HR, 2.10; 95% CI, 1.18-3.71; P = .011). D100 infection-related mortality (IRM) rate was low at 0.2% (95% CI, 0.0-0.8). In this multicenter real-world study, we observed a high incidence of infectious complications but a low IRM following tisa-cel for R/R B-ALL.
Poor sleep quality (PSQ) prevalence in patients with functional dyspepsia (FD): a systematic review and meta-analysis
Netyam, Rashmikaa, Shashank, Singam, Saravanan, Chiranjeevee R, Kolanu, Nikhil Deep, Karra, Nanditha, Hussin, Omniat Amir, Marsool, Mohammed Dheyaa Marsool , Amir, Omniat , Narla, Sai Jahnu Sree Reddy, Prajjwal, Priyadarshi

Annals of Medicine & Surgery | July 30, 2025 | Volume: 87 | Issue: 9 | Pages: 5936-5944

10.1097/ms9.0000000000003616 | PMID 40901125 Get It

Background: Functional dyspepsia (FD), a disease of the gastroduodenal tract, is one of the functional gastrointestinal disorders (FGID) characterized by postprandial fullness and epigastric pain not attributed to any underlying organic diseases. Sleep quality refers to individuals’ satisfaction with their overall sleep, including sleep initiation, maintenance, duration, and feeling refreshed upon waking. Despite frequent associations between sleep disorders and FGID, comprehensive data on poor sleep quality (PSQ) in FD patients is lacking. Therefore, this study was conducted to investigate the occurrence of PSQ in patients with PSQ. Methods: PubMed, Scopus, and Web of Science were systematically searched to identify relevant literature. All studies reporting PSQ prevalence in FD patients or sufficient data to calculate it were included. Pooled prevalence was calculated for all studies, and an odds ratio was determined for studies with a healthy control group. Meta-regression and subgroup analyses assessed the moderating effects of different variables. Publication bias was examined using funnel plots and Egger’s test p-value. The work has been reported in line with AMSTAR (Assessing the methodological quality of systematic reviews) Guidelines. Results: To the best of our knowledge, this is the first study that pooled the estimate of prevalence of patients with FD with PSQ. Based on 2138 FD patients, the pooled prevalence of poor sleep quality is 57.2% (95% CI: 37%–75.2%), I 2 = 98.4%. The asymmetric funnel plot and Egger’s test P-value indicated a significant publication bias for the pooled prevalence estimate. FD patients are at higher risk for poor sleep, with an odds ratio of 2.39 (95% CI: 1.86–3.06), I 2 = 1.73%. Conclusion: Poor sleep is highly prevalent among FD patients, who are more susceptible to poor sleep than healthy individuals. The findings of the study should be interpreted with caution owing to the high heterogeneity and the publication bias observed for the pooled prevalence. Future research should standardize diagnostic parameters and investigate other confounding factors like anxiety and depression to achieve more accurate estimates.
Intraductal Oncocytic Papillary Neoplasm of the Pancreas: A Rare Diagnosis Aided by Next-Generation Sequencing
Gala, Khushboo , Niu, Cathy, Truty, Mark J. , Yi, Eunhee S. , Vege, Santhi Swaroop, Chandrasekhara, Vinay , Truty, Mark, Chandrasekhara, Vinay , Niu, Cathy, Vege, Santhi Swaroop

American Journal of Gastroenterology | July 30, 2025 | Volume: 121 | Issue: 3 | Pages: 581-581

10.14309/ajg.0000000000003660 | PMID 40736676 Get It

Measuring the Risk of Gluten Exposure: Development of the Gluten Exposure Risk Assessment in Pediatric Patients
Hale, Amy E. , Germone, Monique , Fahey, Lisa M. , Stahl, Marisa G. , Leonard, Maureen M. , Singh, Arunjot , Hajjat, Temara , Mallon, Daniel , Kerzner, Benny, Raber, Catherine , Badalyan, Vahe , Mehta, Pooja , Liu, Edwin , Shull, Mary , Absah, Imad , Ediger, Tracy , Jericho, Hilary , Khavari, Nasim, Jossen, Jackie , Wolf, Randi L. , Wong, Madison , Regis, Stephanie , Weisbrod, Vanessa , Silvester, Jocelyn A. , RAISE-CD, Stahl, Marisa , Verma, Ritu , Jericho, Hilary , Wolf, Randi L , Regis, Stephanie , Weisbrod, Vanessa , Silvester, Jocelyn A , Mallon, Daniel , Lee, Dale Young , RAISE-CD

American Journal of Gastroenterology | July 30, 2025 | Volume: 121 | Issue: 5 | Pages: 1251-1258

10.14309/ajg.0000000000003675 | PMID 40736693 Get It

INTRODUCTION: Treatment of celiac disease (CeD) requires a strict gluten-free diet (GFD). Adherence is difficult to assess and influenced by many factors. Identification of potential gluten exposures is essential, but no validated screening measures exist in pediatrics. The aim of this study was to develop and validate a measure screening for gluten exposure risk in pediatric patients with CeD. METHODS: The Gluten Exposure Risk Assessment (GERA) was developed in 3 phases. First, items were generated and refined by a modified Delphi process. Next, psychometrics, factor structure, and validity were examined in a sample of caregivers of pediatric patients younger than 18 years with CeD at 12 pediatric celiac centers. Finally, the final measure was tested on an independent sample population using confirmatory factor analysis and test-retest data. RESULTS: A total of 134 items were generated representing up to 6 domains, with 36 items selected for initial testing. Based on psychometrics and confirmatory factor analysis data from 484 caregivers, the final measure included a total of a single screening question and 9 validated items representing 2 domains (Home, Outside). Repeat testing on a separate sample (N = 369) confirmed factor structure and validity of the final measure (Comparative Fit Index = 0.96, Tucker–Lewis index = 0.95, root mean square error of approximation = 0.06). DISCUSSION: The GERA is a valid screening measure, completed by caregivers, for assessment of gluten exposure in children and adolescents with CeD following a GFD. GERA is a useful tool for evaluating the potential of risk of gluten exposure and potential need for intervention.
Antiphospholipid antibody-related clinical manifestations during childhood versus adulthood: descriptive results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository
Bhatt, Jheel Pandya, Dale, Marissa, Clarke, Ann E. , Aguirre-Zamorano, María Ángeles, Kello, Nina , Wahl, Denis, Branch, Ware, Zhang, Zhuoli , Atsumi, Tatsuya , Pazzola, Giulia, Nalli, Cecilia , Rodríguez-Almaraz, Esther , Petri, Michelle, Artım-Esen, Bahar , Zuo, Yu , Willis, Rohan , Barber, Megan R.W. , Anunciación-Llunell, Ariadna , Erkan, Doruk , Zuo, Yu , Bhatt, Jheel Pandya, Andrade, Danieli , Tektonidou, Maria G. , Pengo, Vittorio , Sciascia, Savino , Gea, Josep Pardos , Paredes, D. , Belmont, H. Michael , Fortin, Paul R. , Wahl, Denis , Gerosa, Maria , Jesús, Guilherme Ramires de , Efthymiou, Maria , Duarte‐García, Alí , Petri, Michelle , Cervera, Ricard , Pons‐Estel, Guillermo , Shi, Hui , Skeith, Leslie , Radin, Massimo , Bertolaccini, Maria Laura , Cohen, Hannah

Clinical and Experimental Rheumatology | July 30, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/t46qkf | PMID 40737058 Get It

Physical activity during pregnancy stratified by body mass index: A focus on class 3 obesity
Nguyen, Eliza M., Szymanski, Linda M. , Branda, Megan E.

Pregnancy | July 30, 2025 | Volume: 1 | Issue: 5 | Pages: No page available

10.1002/pmf2.70083 | PMID 42597077 Get It

Abstract Introduction The prevalence of pre‐pregnancy obesity, including pre‐pregnancy class 3 obesity, has increased over time, with significant implications for maternal and neonatal well‐being. Regular physical activity may mitigate these risks. Available data suggest that most pregnant individuals do not meet the recommended physical activity guidelines of accumulating at least 150 min of moderate‐intensity exercise per week. Importantly, limited data are available regarding physical activity patterns in individuals with higher body mass index (BMI), particularly for those with class 3 obesity (BMI ≥ 40 kg/m 2 ). The aim of this study was to evaluate whether pregnant individuals are meeting physical activity guidelines. We assessed self‐reported physical activity across BMI categories including those with class 3 obesity, further subdivided into BMI of 40–49.9 and ≥ 50 kg/m 2 . Methods This is a retrospective cohort study of individuals at an academic hospital system who delivered between May 1, 2018 and May 1, 2023. To be included, individuals had to respond to the following two‐item physical activity questionnaire early in pregnancy: (1) “On average, how many days per week do you engage in moderate to strenuous exercise?” And (2) “On average, how many minutes do you engage in exercise at this level?” From these two questions, total minutes per week of activity were calculated. Individuals met physical activity guidelines if they engaged in ≥ 150 min of physical activity per week. Data were analyzed using Kruskal–Wallis and Chi‐square tests. Results A total of 6884 individuals were incl uded in the cohort. A total of 510 individuals met the criteria for class 3 obesity, with 61 having a pre‐pregnancy BMI ≥ 50 kg/m 2 . Among normal weight individuals (BMI 18.5–24.9 kg/m 2 ), 34% met physical activity guidelines. Overweight and obese individuals were significantly less physically active than those with normal BMI ( p < 0.05). Only 22% of those with BMI 40–49.9 kg/m 2 and 18% of those with BMI ≥ 50 kg/m 2 reported sufficient physical activity. Conclusion Our results are consistent with existing data, showing that pregnant individuals are not meeting physical activity goals. Pregnant individuals who are overweight or obese engage in significantly less physical activity compared to those with a BMI in the normal range, with the lowest levels of activity observed among individuals with class 3 obesity. More data are needed on physical activity among pregnant individuals with class 3 obesity, including evaluation of potential interventions to increase activity as well as barriers to participation. Increasing physical activity in this group may positively impact both maternal and neonatal health.